 |
|
 |
|
|
Clinical Trial in Multiple Sclerosis
Active Enrolling
Active Closed for Enrollment
- Achieve 9013 - compare the total number of confirmed relapses experienced by the patients randomized to continue their current high-dose of IFN therapy (Betaseron® 250 µg or Rebif® 44 µg) to that observed in patients randomized to GA (Copaxone®) treatment
- Pre-Beyond 307320 – offer extension of treatment to all patients with RRMS who completed full treatment in the double-blind, randomized, parallel group, multicenter study 307000A, and to further assess the safety and tolerability of Betaseron® 500 µg QOD and 250 µg QOD in these patients
-
Bayer- Beyond Follow-up- International, multicenter, Phase IIIb study of subcutaneous everyother- day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 μg or 500 μg or open-label Betaseron/Betaferon 250 μg and (Phase B) open-label Betaseron/Betaferon 500 μg
BEYOND Follow-up study
- Choice DAC-1012 – evaluate the efficacy of daclizumab in patients who have active, relapsing forms of MS and are currently on IFN-beta therapy
- Regard 24735 – compare the time to first relapse of subjects treated with Rebif® 44 mcg three times per week (132 mcg per week) with that of subjects treated with Copaxone® 20 mg daily during 96 weeks of treatment
- Pilot Study – A Pilot Study of MRI Spectroscopy, Diffusion Tensor Imaging, and Magnetization Transfer Imaging in multiple sclerosis
- Forte 9016
- Serono 27133 Rebif-Betaseron
Completed
|
|
|
|
|